Literature DB >> 8081414

The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.

M Armstrong1, K Fairbrother, J R Idle, A K Daly.   

Abstract

DNA from two subjects showing anomalous CYP2D6 phenotype-genotype relationships was analysed for the presence of new CYP2D6 mutations by single strand conformational polymorphism (SSCP) analysis. One of these subjects was homozygous for polymorphisms in exon 1 and exon 9 previously detected in Oriental populations and termed the CYP2D6J allele. The frequency of these polymorphisms and their effect on phenotype was investigated in a European population with a small Chinese population as a control group. Subjects homozygous for both polymorphisms showed impaired metabolism of debrisoquine whereas subjects with the exon 9 mutation only appeared to show similar metabolism to the wild-type. The CYP2D6J allele frequency was 0.05 in the European group compared with 0.47 for the Chinese group. The relationship between the CYP2D6J allele and the exon 9 polymorphism and the presence of insertions upstream of CYP2D6 detectable by RFLP analysis with Xba I was investigated. In the Chinese group the insertion appeared to be associated with the CYP2D6J allele but in the European group no association was detected. Subjects homozygous for the CYP2D6J allele appear to show a similar debrisoquine phenotype to those heterozygous for CYP2D6-inactivating mutations but the exon 9 polymorphism or the presence of an upstream insertion without an associated CYP2D6B or CYP2D6J allele does not appear to affect enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081414     DOI: 10.1097/00008571-199404000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  9 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

2.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Authors:  Jennifer Lee; Selina Moy; John Meijer; Walter Krauwinkel; Taiji Sawamoto; Virginie Kerbusch; Donna Kowalski; Michael Roy; Alan Marion; Shin Takusagawa; Marcel van Gelderen; James Keirns
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

6.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

7.  Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.

Authors:  Tohru Ohnuma; Nobuto Shibata; Yoichiro Matsubara; Heii Arai
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

8.  An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.

Authors:  A K Daly; J B Leathart; S J London; J R Idle
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

9.  Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.

Authors:  Takao Yamazaki; Amit Desai; Ronald Goldwater; David Han; Corrie Howieson; Shahzad Akhtar; Donna Kowalski; Christopher Lademacher; Helene Pearlman; Diane Rammelsberg; Robert Townsend
Journal:  Clin Pharmacol Drug Dev       Date:  2016-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.